当前位置: 首页 > 期刊 > 《中国当代医药》 > 2019年第20期
编号:13419197
雷贝拉唑联合莫沙必利治疗胃食管反流性咽喉炎的效果与安全性(1)
http://www.100md.com 2019年7月15日 《中国当代医药》 2019年第20期
     [摘要]目的 探讨雷贝拉唑联合莫沙必利治疗胃食管反流性咽喉炎的效果与安全性。方法 选取2015年3月~2018年3月我院收治的84例胃食管反流性咽喉炎患者作为研究对象,按照随机数字表法将其分成对照组和观察组,每组各42例。对照组患者给予雷贝拉唑治疗,观察组患者给予雷贝拉唑联合莫沙必利治疗,比较两组患者的治疗效果、食管下括约肌压力、血清胃泌素及不良反应发生情况。结果 观察组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后的食管下括约肌压力、血清胃泌素水平高于对照组,差异有统计学意义(P<0.05);观察组患者的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论 雷贝拉唑联合莫沙必利治疗胃食管反流性咽喉炎可有效提高患者的治疗效果,改善食管下括约肌压力、血清胃泌素水平,降低不良反应总发生率,可行性高。

    [关键词]胃食管反流性咽喉炎;雷贝拉唑;莫沙必利;食管下括约肌压力;血清胃泌素

    [中图分类号] R573.3 [文献标识码] A [文章编号] 1674-4721(2019)7(b)-0123-04

    [Abstract] Objective To investigate the efficacy and safety of Rabeprazole combined with Mosapride in the treatment of gastroesophageal reflux laryngitis. Methods A total of 84 patients with gastroesophageal reflux laryngitis admitted to our hospital from March 2015 to March 2018 were selected as objects and divided into control group and observation group according to random number table method. There were 42 cases in each groups. The control group was treated with Rabeprazole, while the observation group was treated with Rabeprazole combined with Mosapride. The therapeutic effects, lower esophageal sphincter pressure, serum gastrin and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group with statistical significance (P<0.05); the pressure of lower esophageal sphincter and serum gastrin in the observation group were higher than those in the control group after treatment (P<0.05); the total incidence of adverse reactions in the observation group was lower than that in the control group with statistical significance (P<0.05). Conclusion Rabeprazole combined with Mosapride in the treatment of gastroesophageal reflux laryngitis can effectively improve the therapeutic effect of patients, improve the lower esophageal sphincter pressure, serum gastrin level, reduce the incidence of adverse reactions, high feasibility.

    [Key words] Gastroesophageal reflux laryngitis; Rabeprazole; Mosapride; Lower esophageal sphincter pressure; Serum gastrin

    胃食管反流是消化內科常见的一种疾病,常发生于老年人群中,在肥胖、酗酒、精神压力较大的人群中也有较高的发病率。随着人们不良生活方式的增多,饮食结构的多样化,导致该病的发病人数逐年增加。咽喉炎是临床上的常见疾病,而胃食管反流性咽喉炎主要是因十二指肠及胃内容物反流进入食管,造成食管黏膜受损,其症状常表现为反酸、胃部灼烧感等,不仅影响患者的身体健康,也降低了其生活质量[1]。相关研究报道显示,胃食管反流患者中存在咽喉炎的比例约为72.0%,其中因胃食管反流导致的咽喉炎患者为47.7%。临床常规治疗以抑制咽喉炎发展为主要目的,但在胃食管反流性咽喉炎患者的治疗中效果不佳,而联合其他利于胃肠道蠕动的药物及质子泵抑制剂治疗可行性及安全性较高[2]。雷贝拉唑是临床上常用的抗溃疡药物,而莫沙必利可减少胃酸反流概率,利于胃酸的排空[3]。本研究旨在探讨胃食管反流性咽喉炎患者采用雷贝拉唑与莫沙必利联合治疗的效果,现报道如下。, http://www.100md.com(熊子云)
1 2 3下一页